Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma

Table 1

Clinical feature of TCGA-UCEC cohort.

	ARID1A-mut	ARID1A-wild	value
SAMPLE	233	288
AGE	61.49 ± 10.66	65.89 ± 11.02	<0.001
BMI	34.11 ± 15.06	33.54 ± 9.28	0.608
STAGE			0.009
Stage I	164 (70.39%)	159 (55.21%)
Stage II	21 (9.02%)	29 (10.07%)
Stage III	44 (18.87%)	77 (26.73%)
Stage IV	4 (1.72%)	23 (7.99%)
DIABETES			0.76
NO	120 (74.07%)	138 (72.63%)
YES	42 (25.93%)	52 (27.37%)
HYPERTENSION			0.992
NO	75 (42.37%)	84 (42.42%)
YES	102 (57.63%)	114 (57.58%)
GRADE			0.025
G1	52 (22.32%)	44 (15.28%)
G2	58 (24.89%)	57 (19.79%)
G3	121 (51.93%)	180 (62.50%)
High grade	2 (0.86%)	7 (2.43%)
STATUS			<0.001
Alive	213 (91.42%)	223 (77.43%)
Dead	20 (8.58%)	65 (22.57%)